Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer.

FAPI cancer-associated fibroblasts interobserver variability pancreatic cancer target definition

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Feb 2021
Historique:
received: 19 01 2021
revised: 06 02 2021
accepted: 11 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 7 3 2021
Statut: epublish

Résumé

(1) Background: A new radioactive positron emission tomography (PET) tracer uses inhibitors of fibroblast activation protein (FAPI) to visualize FAP-expressing cancer associated fibroblasts. Significant FAPI-uptake has recently been demonstrated in pancreatic cancer patients. Target volume delineation for radiation therapy still relies on often less precise conventional computed tomography (CT) imaging, especially in locally recurrent pancreatic cancer patients. The need for improvement in precise tumor detection and delineation led us to innovatively use the novel FAPI-PET/CT for radiation treatment planning. (2) Methods: Gross tumor volumes (GTVs) of seven locally recurrent pancreatic cancer cases were contoured by six radiation oncologists. In addition, FAPI-PET/CT was used to automatically delineate tumors. The interobserver variability in target definition was analyzed and FAPI-based automatic GTVs were compared to the manually defined GTVs. (3) Results: Target definition differed significantly between different radiation oncologists with mean dice similarity coefficients (DSCs) between 0.55 and 0.65. There was no significant difference between the volumes of automatic FAPI-GTVs based on the threshold of 2.0 and most of the manually contoured GTVs by radiation oncologists. (4) Conclusion: Due to its high tumor to background contrast, FAPI-PET/CT seems to be a superior imaging modality compared to the current gold standard contrast-enhanced CT in pancreatic cancer. For the first time, we demonstrate how FAPI-PET/CT could facilitate target definition and increases consistency in radiation oncology in pancreatic cancer.

Identifiants

pubmed: 33672893
pii: cancers13040796
doi: 10.3390/cancers13040796
pmc: PMC7918160
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Medizinischen Fakultät Heidelberg, Universität Heidelberg
ID : Physician Scientist Program

Références

Acta Oncol. 2019 Apr;58(4):439-447
pubmed: 30632876
Clin Transl Radiat Oncol. 2020 Apr 13;22:90-97
pubmed: 32337377
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832219
J Nucl Med. 2020 Oct 23;:
pubmed: 33097632
Radiat Oncol. 2013 Jan 31;8:27
pubmed: 23369246
Abdom Radiol (NY). 2016 Feb;41(2):273-82
pubmed: 26867909
Radiother Oncol. 2019 Aug;137:9-15
pubmed: 31048235
Comput Med Imaging Graph. 2006 Mar;30(2):75-87
pubmed: 16584976
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Pancreatology. 2016 Nov - Dec;16(6):1124-1128
pubmed: 27717684
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Eur Radiol. 2019 Apr;29(4):1961-1967
pubmed: 30302589
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2836-2845
pubmed: 32447444
Radiology. 2018 May;287(2):374-390
pubmed: 29668413
Radiother Oncol. 2020 Mar;144:152-158
pubmed: 31812930
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Mol Carcinog. 2020 Jul;59(7):754-765
pubmed: 32363633
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
J Hematol Oncol. 2017 Mar 28;10(1):76
pubmed: 28351381
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
J Nucl Med Technol. 2015 Jun;43(2):92-7
pubmed: 25857417
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3
pubmed: 16168826
Cancers (Basel). 2020 May 25;12(5):
pubmed: 32466266
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Strahlenther Onkol. 2014 May;190(5):485-90
pubmed: 24599344
Radiother Oncol. 2018 Oct;129(1):101-104
pubmed: 29463433
Eur J Radiol. 2018 Sep;106:128-136
pubmed: 30150034

Auteurs

Jakob Liermann (J)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.

Mustafa Syed (M)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.

Edgar Ben-Josef (E)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Kai Schubert (K)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Ingmar Schlampp (I)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Simon David Sprengel (SD)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Jonas Ristau (J)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Fabian Weykamp (F)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Manuel Röhrich (M)

Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Stefan A Koerber (SA)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Uwe Haberkorn (U)

Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Juergen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK), Partner Site Heidelberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Klaus Herfarth (K)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK), Partner Site Heidelberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Frederik L Giesel (FL)

Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Patrick Naumann (P)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Classifications MeSH